Omega-3 and Zinc Supplementation As Complementary Therapies in Children with Attention-deficit/hyperactivity Disorder

Overview

Journal J Res Pharm Pract

Date 2016 Mar 18

PMID 26985432

Citations 16

Authors

Bahman Salehi

Abolfazl Mohammadbeigi

Hamid Sheykholeslam

Esmail Moshiri

Fatemeh Dorreh

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study is to evaluate the effect of zinc and omega-3 supplements as adjunctive drugs in the treatment of attention-deficit/hyperactivity disorder (ADHD) of children.

Methods: This study is a randomized, double-blind clinical trial conducted on 150 children aged 6-15 years old that diagnosed as new cases of ADHD. Study subjects were evaluated for 8 weeks. Besides of drug of choice (methylphenidate) for the ADHD, patients received placebo in the control group (n = 50), zinc sulfate in second group (n = 50), and omega-3 (n = 50) in third group. Clinical improvement was checking by Conners' Parent and Teacher Rating Scales before and in 2(nd), 4(th), and 8(th) week of treatment. Results were analyzed with SPSS version 16 software.

Findings: In this study, mean scores of Conners' scale showed significant improvement during treatment in the zinc group compared to control group in children that affected to attention-deficit disorder subtype of ADHD (P = 0.02). Moreover, in omega-3 group, better clinical response was seen than other groups (P < 0.05). However, there was no significant difference between omega-3 group compared to placebo group in the mean scores of Conners' scale (P = 0.89).

Conclusion: Zinc supplementation accompanied by the main treatment significantly improves symptom of attention-deficit disorder subtype of ADHD. However, omega-3 supplementation was superior to zinc and placebo in the clinical improvement of ADHD.

Citing Articles

A systematic review of the beneficial effects of prebiotics, probiotics, and synbiotics on ADHD.

Allahyari P, Abbas Torki S, Aminnezhad Kavkani B, Mahmoudi Z, Hoseini M, Moradi M Neuropsychopharmacol Rep. 2024; 44(2):300-307.

PMID: 38623929 PMC: 11144606. DOI: 10.1002/npr2.12437.

Safety and efficacy of antioxidant therapy in children and adolescents with attention deficit hyperactivity disorder: A systematic review and network meta-analysis.

Zhou P, Yu X, Song T, Hou X PLoS One. 2024; 19(3):e0296926.

PMID: 38547138 PMC: 10977718. DOI: 10.1371/journal.pone.0296926.

Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.

Gillies D, Leach M, Perez Algorta G Cochrane Database Syst Rev. 2023; 4:CD007986.

PMID: 37058600 PMC: 10103546. DOI: 10.1002/14651858.CD007986.pub3.

Neurodevelopmental Consequences of Dietary Zinc Deficiency: A Status Report.

Ross M, Hernandez-Espinosa D, Aizenman E Biol Trace Elem Res. 2023; 201(12):5616-5639.

PMID: 36964812 DOI: 10.1007/s12011-023-03630-2.

Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children.

Carucci S, Romaniello R, Demuru G, Curatolo P, Grelloni C, Masi G Eur Arch Psychiatry Clin Neurosci. 2022; 272(8):1453-1467.

PMID: 35672606 DOI: 10.1007/s00406-022-01428-2.

References

Antalis C, Stevens L, Campbell M, Pazdro R, Ericson K, Burgess J . Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2006; 75(4-5):299-308. DOI: 10.1016/j.plefa.2006.07.004. View

Akhondzadeh S, Mohammadi M, Khademi M . Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 2004; 4:9. PMC: 400741. DOI: 10.1186/1471-244X-4-9. View

Huss M, Volp A, Stauss-Grabo M . Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems - an observational cohort study. Lipids Health Dis. 2010; 9:105. PMC: 2955638. DOI: 10.1186/1476-511X-9-105. View

Lepping P, Huber M . Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment. CNS Drugs. 2010; 24(9):721-8. DOI: 10.2165/11537610-000000000-00000. View

Busch B . Polyunsaturated fatty acid supplementation for ADHD? Fishy, fascinating, and far from clear. J Dev Behav Pediatr. 2007; 28(2):139-44. DOI: 10.1097/01.DBP.0000267560.34199.e0. View

Oner O, Oner P, Hekim Bozkurt O, Odabas E, Keser N, Karadag H . Effects of zinc and ferritin levels on parent and teacher reported symptom scores in attention deficit hyperactivity disorder. Child Psychiatry Hum Dev. 2010; 41(4):441-7. PMC: 3399584. DOI: 10.1007/s10578-010-0178-1. View

Yorbik O, Ozdag M, Olgun A, Guney Senol M, Bek S, Akman S . Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 32(3):662-7. DOI: 10.1016/j.pnpbp.2007.11.009. View

Belanger S, Vanasse M, Spahis S, Sylvestre M, Lippe S, LHeureux F . Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009; 14(2):89-98. PMC: 2661342. DOI: 10.1093/pch/14.2.89. View

Sinn N . Polyunsaturated fatty acid supplementation for ADHD symptoms: response to commentary. J Dev Behav Pediatr. 2007; 28(3):262-3. DOI: 10.1097/DBP.0b013e3180de4cd5. View

10.

Dodig-Curkovic K, Dovhanj J, Curkovic M, Dodig-Radic J, Degmecic D . [The role of zinc in the treatment of hyperactivity disorder in children]. Acta Med Croatica. 2009; 63(4):307-13. View

11.

Toplak M, Pitch A, Flora D, Iwenofu L, Ghelani K, Jain U . The unity and diversity of inattention and hyperactivity/impulsivity in ADHD: evidence for a general factor with separable dimensions. J Abnorm Child Psychol. 2009; 37(8):1137-50. DOI: 10.1007/s10802-009-9336-y. View

12.

Schmidt S, Stahl F, Mutz K, Scheper T, Hahn A, Schuchardt J . Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men. Nutr Metab (Lond). 2012; 9(1):45. PMC: 3408332. DOI: 10.1186/1743-7075-9-45. View

13.

Rojas N, Chan E . Old and new controversies in the alternative treatment of attention-deficit hyperactivity disorder. Ment Retard Dev Disabil Res Rev. 2005; 11(2):116-30. DOI: 10.1002/mrdd.20064. View

14.

Bilici M, Yildirim F, Kandil S, Bekaroglu M, Yildirmis S, Deger O . Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 28(1):181-90. DOI: 10.1016/j.pnpbp.2003.09.034. View

15.

Eugene Arnold L, Bozzolo H, Hollway J, Cook A, DiSilvestro R, Bozzolo D . Serum zinc correlates with parent- and teacher- rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005; 15(4):628-36. DOI: 10.1089/cap.2005.15.628. View